These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 10037394)

  • 1. Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma.
    Adler HL; McCurdy MA; Kattan MW; Timme TL; Scardino PT; Thompson TC
    J Urol; 1999 Jan; 161(1):182-7. PubMed ID: 10037394
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tissue expression of transforming growth factor-beta1 and its receptors: correlation with pathologic features and biochemical progression in patients undergoing radical prostatectomy.
    Shariat SF; Menesses-Diaz A; Kim IY; Muramoto M; Wheeler TM; Slawin KM
    Urology; 2004 Jun; 63(6):1191-7. PubMed ID: 15183988
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma levels of transforming growth factor-1beta and alpha2-macroglobulin before and after radical prostatectomy: association to clinicopathological parameters.
    Sinnreich O; Kratzsch J; Reichenbach A; Gläser C; Huse K; Birkenmeier G
    Prostate; 2004 Nov; 61(3):201-8. PubMed ID: 15368477
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The addition of interleukin-6 soluble receptor and transforming growth factor beta1 improves a preoperative nomogram for predicting biochemical progression in patients with clinically localized prostate cancer.
    Kattan MW; Shariat SF; Andrews B; Zhu K; Canto E; Matsumoto K; Muramoto M; Scardino PT; Ohori M; Wheeler TM; Slawin KM
    J Clin Oncol; 2003 Oct; 21(19):3573-9. PubMed ID: 12913106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transforming growth factor-beta1 serum concentration in patients with prostatic cancer and benign prostatic hyperplasia.
    Wolff JM; Fandel T; Borchers H; Brehmer B; Jakse G
    Br J Urol; 1998 Mar; 81(3):403-5. PubMed ID: 9523660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transforming growth factor-beta 1: comparative immunohistochemical localization in human primary and metastatic prostate cancer.
    Eastham JA; Truong LD; Rogers E; Kattan M; Flanders KC; Scardino PT; Thompson TC
    Lab Invest; 1995 Nov; 73(5):628-35. PubMed ID: 7474936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preoperative serum prostate specific antigen does not reflect biochemical failure rates after radical prostatectomy in men with large volume cancers.
    Noguchi M; Stamey TA; McNeal JE; Yemoto CM
    J Urol; 2000 Nov; 164(5):1596-600. PubMed ID: 11025712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lack of association of prostate carcinoma nuclear grading with prostate specific antigen recurrence after radical prostatectomy.
    Zhou M; Hayasaka S; Taylor JM; Shah R; Proverbs-Singh T; Manley S; Rubin MA
    J Urol; 2001 Dec; 166(6):2193-7. PubMed ID: 11696734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early postoperative plasma transforming growth factor-beta1 is a strong predictor of biochemical progression after radical prostatectomy.
    Shariat SF; Walz J; Roehrborn CG; Montorsi F; Jeldres C; Saad F; Karakiewicz PI
    J Urol; 2008 Apr; 179(4):1593-7. PubMed ID: 18295256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum interleukin 6 as a prognostic factor in patients with prostate cancer.
    Nakashima J; Tachibana M; Horiguchi Y; Oya M; Ohigashi T; Asakura H; Murai M
    Clin Cancer Res; 2000 Jul; 6(7):2702-6. PubMed ID: 10914713
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transforming growth factor beta as a clinical biomarker for prostate cancer.
    Perry KT; Anthony CT; Case T; Steiner MS
    Urology; 1997 Jan; 49(1):151-5. PubMed ID: 9000208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is preoperative serum prostate-specific antigen level significantly related to clinical recurrence after radical retropubic prostatectomy for localized prostate cancer?
    Haukaas SA; Halvorsen OJ; Daehlin L; Hostmark J; Akslen LA
    BJU Int; 2006 Jan; 97(1):51-5. PubMed ID: 16336328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The percent of cores positive for cancer in prostate needle biopsy specimens is strongly predictive of tumor stage and volume at radical prostatectomy.
    Sebo TJ; Bock BJ; Cheville JC; Lohse C; Wollan P; Zincke H
    J Urol; 2000 Jan; 163(1):174-8. PubMed ID: 10604340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum levels of transforming growth factor beta1 are significantly correlated with venous invasion in patients with gastric cancer.
    Lin Y; Kikuchi S; Obata Y; Yagyu K;
    J Gastroenterol Hepatol; 2006 Feb; 21(2):432-7. PubMed ID: 16509870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transforming growth factor-beta1 and renal cell cancer: cell growth, mRNA expression and protein production of cytokines.
    Shimabukuro T; Ohmoto Y; Naito K
    J Urol; 2003 May; 169(5):1865-9. PubMed ID: 12686863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum concentrations of transforming growth factor-beta 1 in patients with benign and malignant prostatic diseases.
    Wolff JM; Fandel TH; Borchers H; Jakse G
    Anticancer Res; 1999; 19(4A):2657-9. PubMed ID: 10470214
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum macrophage inhibitory cytokine-1 concentrations correlate with the presence of prostate cancer bone metastases.
    Selander KS; Brown DA; Sequeiros GB; Hunter M; Desmond R; Parpala T; Risteli J; Breit SN; Jukkola-Vuorinen A
    Cancer Epidemiol Biomarkers Prev; 2007 Mar; 16(3):532-7. PubMed ID: 17372249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased urokinase-type plasminogen activator receptor and epidermal growth factor receptor in serum of patients with prostate cancer.
    Milanese G; Dellabella M; Fazioli F; Pierpaoli E; Polito M; Siednius N; Montironi R; Blasi F; Muzzonigro G
    J Urol; 2009 Mar; 181(3):1393-400. PubMed ID: 19157433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elevation of cytokine levels in cachectic patients with prostate carcinoma.
    Pfitzenmaier J; Vessella R; Higano CS; Noteboom JL; Wallace D; Corey E
    Cancer; 2003 Mar; 97(5):1211-6. PubMed ID: 12599227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.
    Cheng L; Jones TD; Lin H; Eble JN; Zeng G; Carr MD; Koch MO
    J Urol; 2005 Dec; 174(6):2181-5. PubMed ID: 16280760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.